RxDoctor Payments Data

Erica Fowler

Family · Fort Smith, ARNPI 1417613704

Payments from drug & device makers

$677in general payments, 2019–2025

Across 43 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$183
  • Otsuka America Pharmaceutical, Inc.$107
  • Exact Sciences$63
  • Lilly USA, LLC$55
  • Novo Nordisk$49
  • AstraZeneca$47
  • plus $174 from 10 others

What the payments were for

  • Food & beverage$677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$677 in reported general payments places this provider in the 60th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,408
Medicare patients
53
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$80,850
FarxigaDapagliflozin Propanediol69$72,470
JanuviaSitagliptin Phosphate59$49,078
OzempicSemaglutide34$32,792
EliquisApixaban12$16,507
XareltoRivaroxaban12$13,713
TradjentaLinagliptin14$13,007
LinzessLinaclotide16$11,020
JanumetSitagliptin Phos/Metformin Hcl12$7,180
SymbicortBudesonide/Formoterol Fumarate14$5,051
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$4,287
Levemir FlexpenInsulin Detemir18$3,465
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,325
Sucralfate16$1,985
Atorvastatin Calcium390$1,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$47$77,52183 claims
MerckJanuvia, Janumet$15$56,25871 claims
Novo NordiskOzempic$49$32,79234 claims
AbbVieLinzess$183$11,02016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,103 family providers in Arkansas.

Other family in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →